Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia
Gautam Borthakur, Susan O'BrienDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USAAbstract: Targeted inhibition of the Bcl-2 family of antiapoptotic proteins is expected to improve outcomes in chronic lymphocytic leukemia. Antisense oligonucleotides and small molecule inh...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a27198548c2a43719d407886196132a3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a27198548c2a43719d407886196132a3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a27198548c2a43719d407886196132a32021-12-02T05:07:26ZPharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia1179-9889https://doaj.org/article/a27198548c2a43719d407886196132a32012-08-01T00:00:00Zhttp://www.dovepress.com/pharmacology-and-clinical-potential-of-oblimersen-sodium-in-the-treatm-a10754https://doaj.org/toc/1179-9889Gautam Borthakur, Susan O'BrienDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USAAbstract: Targeted inhibition of the Bcl-2 family of antiapoptotic proteins is expected to improve outcomes in chronic lymphocytic leukemia. Antisense oligonucleotides and small molecule inhibitors (BH3 mimetics) are two approaches that have been used to target Bcl-2 proteins. In this review, we summarize the experience with oblimersen sodium, an 18-base oligonucleotide targeting the first six codons of Bcl-2 mRNA, with particular focus on chronic lymphocytic leukemia. Despite evidence of improved outcomes in randomized trials of combination with chemoimmunotherapy, further development of this antisense approach has been slow, likely because of the clinical development of small molecule inhibitors.Keywords: oblimersen, Bcl-2, antisense, chronic lymphocytic leukemiaO'Brien SBorthakur GDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 137-143 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Diseases of the blood and blood-forming organs RC633-647.5 O'Brien S Borthakur G Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| description |
Gautam Borthakur, Susan O'BrienDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USAAbstract: Targeted inhibition of the Bcl-2 family of antiapoptotic proteins is expected to improve outcomes in chronic lymphocytic leukemia. Antisense oligonucleotides and small molecule inhibitors (BH3 mimetics) are two approaches that have been used to target Bcl-2 proteins. In this review, we summarize the experience with oblimersen sodium, an 18-base oligonucleotide targeting the first six codons of Bcl-2 mRNA, with particular focus on chronic lymphocytic leukemia. Despite evidence of improved outcomes in randomized trials of combination with chemoimmunotherapy, further development of this antisense approach has been slow, likely because of the clinical development of small molecule inhibitors.Keywords: oblimersen, Bcl-2, antisense, chronic lymphocytic leukemia |
| format |
article |
| author |
O'Brien S Borthakur G |
| author_facet |
O'Brien S Borthakur G |
| author_sort |
O'Brien S |
| title |
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| title_short |
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| title_full |
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| title_fullStr |
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| title_full_unstemmed |
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| title_sort |
pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/a27198548c2a43719d407886196132a3 |
| work_keys_str_mv |
AT oamp39briens pharmacologyandclinicalpotentialofoblimersensodiuminthetreatmentofchroniclymphocyticleukemia AT borthakurg pharmacologyandclinicalpotentialofoblimersensodiuminthetreatmentofchroniclymphocyticleukemia |
| _version_ |
1718400611119005696 |